147 related articles for article (PubMed ID: 26383741)
1. Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome.
Wang C; Su W; Cai QQ; Cai H; Ji W; Di Q; Duan MH; Cao XX; Zhou DB; Li J
Eur J Haematol; 2016 Jul; 97(1):48-54. PubMed ID: 26383741
[TBL] [Abstract][Full Text] [Related]
2. Free light chains and heavy/light chains in monitoring POEMS patients.
Altinier S; Proko K; Zaninotto M; Ciubotaru D; Seguso M; Varagnolo M; Lessi F; Briani C; Adami F; Plebani M
Clin Chem Lab Med; 2016 Jun; 54(6):1065-71. PubMed ID: 27071150
[TBL] [Abstract][Full Text] [Related]
3. Serum immunoglobulin free light chain and heavy/light chain measurements in POEMS syndrome.
Wang C; Su W; Zhang W; Di Q; Duan MH; Ji W; Cao XX; Zhou DB; Li J
Ann Hematol; 2014 Jul; 93(7):1201-6. PubMed ID: 24482101
[TBL] [Abstract][Full Text] [Related]
4. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.
Stankowski-Drengler T; Gertz MA; Katzmann JA; Lacy MQ; Kumar S; Leung N; Hayman SR; Buadi F; Kyle RA; Rajkumar SV; Dispenzieri A
Am J Hematol; 2010 Jun; 85(6):431-4. PubMed ID: 20513121
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
7. POEMS Syndrome with IgG-λ/IgA-κ Biclonal Gammopathy and Abnormal Serum Free Light Chain Ratio: a Case Report.
Ham JY; Suh JS; Lee WK; Song KE
Ann Clin Lab Sci; 2015; 45(6):702-6. PubMed ID: 26663802
[TBL] [Abstract][Full Text] [Related]
8. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
[TBL] [Abstract][Full Text] [Related]
9. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.
Kraj M
Adv Clin Exp Med; 2014; 23(1):127-33. PubMed ID: 24596015
[TBL] [Abstract][Full Text] [Related]
11. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
[TBL] [Abstract][Full Text] [Related]
13. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
15. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.
Bradwell A; Harding S; Fourrier N; Mathiot C; Attal M; Moreau P; Harousseau JL; Avet-Loiseau H
Leukemia; 2013 Jan; 27(1):202-7. PubMed ID: 22699454
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) - Benefit for Stratification of Multiple Myeloma?].
Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
[TBL] [Abstract][Full Text] [Related]
19. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
Katzmann JA; Clark R; Kyle RA; Larson DR; Therneau TM; Melton LJ; Benson JT; Colby CL; Dispenzieri A; Landgren O; Kumar S; Bradwell AR; Cerhan JR; Rajkumar SV
Leukemia; 2013 Jan; 27(1):208-12. PubMed ID: 22781594
[TBL] [Abstract][Full Text] [Related]
20. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]